SIR, In six patients with systemic sclerosis (SSc) and interstitial lung disease (ILD), Liossis et
al.[1] reported pulmonary function improvements following first-line treatment with …

After 3 weeks, the muscle pain and skin manifestations had improved, while the chest
images had deteriorated gradually with lung shrinkage on chest X-ray and increasing GGA …

Systemic sclerosis (SSc) is a rare multisystem connective tissue disease of unclear etiology
in which vascular dysfunction, fibrosis of the skin and internal organs, and autoimmunity …

Background Scleroderma is a systemic autoimmune disease characterized mainly by skin
manifestations and involvement of various visceral organs, especially the lungs. Lung …

Up to 80% of patients with scleroderma have lung disease, with interstitial lung disease
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …

Objective. To report the efficacy and tolerability of mycophenolate mofetil (MMF) and
azathioprine (AZA) in the management of systemic sclerosis-associated interstitial lung …

Objective To compare mycophenolate mofetil (MMF) with placebo for the treatment of
systemic sclerosis (SSc)–related interstitial lung disease (ILD). Methods We included …

Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However …

Mycophenolate mofetil (MMF) is an antimetabolite with a potent inhibitory effect on
proliferation of T and B lymphocytes used since the early 1990s for the prevention of acute …

To assess the effect of mycophenolate mofetil (MMF) on pulmonary functions in patients with
systemic sclerosis‐associated lung disease (SS c‐ILD) who experienced an inadequate …